Pediatric pulmonology
Authors: Espuela-Ortiz A, Lorenzo-Diaz F, Baez-Ortega A, Eng C, Hernandez-Pacheco N, Oh SS, Lenoir M, Burchard EG, Flores C, Pino-Yanes M
Journal of the National Cancer Institute
Authors: Samet JM, Chiu WA, Cogliano V, Jinot J, Kriebel D, Lunn RM, Beland FA, Bero L, Browne P, Fritschi L, Kanno J, Lachenmeier DW, Lan Q, Lasfargues G, Curieux FL, Peters S, Shubat P, Sone H, White MC, Williamson J, Yakubovskaya M, Siemiatycki J, White PA, Guyton KZ, Schubauer-Berigan MK, Hall AL, Grosse Y, Bouvard V, Benbrahim-Tallaa L, Ghissassi FE, Lauby-Secretan B, Armstrong B, Saracci R, Zavadil J, Straif K, Wild CP
Alimentary pharmacology & therapeutics
Authors: Williams FR, Berzigotti A, Lord JM, Lai JC, Armstrong MJ
Transplantation
Authors: Mazumder N, Atiemo K, Kappus M, Cullaro G, Harinstein ME, Ladner D, Verna E, Lai J, Levitsky J
Gastroenterology
Authors: Mahadevan U, Fisher S, Riley L, Chambers C, Jain R, Robinson C
The Lancet. Respiratory medicine
Authors: Benowitz NL
The Journal of allergy and clinical immunology
Authors: Li X, Hastie AT, Peters MC, Hawkins GA, Phipatanakul W, Li H, Moore WC, Busse WW, Castro M, Erzurum SC, Gaston B, Israel E, Jarjour NN, Levy BD, Wenzel SE, Meyers DA, Fahy JV, Bleecker ER
Volume 21 of Issue 10 | Current cardiology reports
Authors: Kachur S, Morin DP
PURPOSE OF REVIEW
To discuss the role of wearable cardioverter defibrillator (WCD) vests in preventing sudden cardiac death (SCD) in at-risk populations.
RECENT FINDINGS
The impact of randomized-controlled trials with implantable cardioverter-defibrillators (ICD) therapy is well established in randomized clinical trials in ischemic cardiomyopathy. Although the benefits are not as clear in non-ischemic cardiomyopathy, meta-analyses show significant mortality benefits from immediate electrical cardioversion strategies. The role of WCDs in at-risk populations in whom ICD therapy is temporarily not indicated is not as well-established. Smaller cohort trials have shown efficacy in patients with newly-diagnosed cardiomyopathy, requiring temporary ICD explantation, and others with less common indications for WCD therapy. The Vest Prevention of Early Sudden Death Trial was a landmark randomized control study seeking to examine the benefits of WCD therapy in at-risk population, and although the primary endpoint of reducing arrhythmic death was not reached, the structure of the trial and significant differences in total mortality make a compelling case for continued use of WCD therapies in our healthcare systems.
View on PubMed
International journal of molecular sciences
Authors: Howe M, Bauer J, Schulze A, Kropp S, Locksley RM, Alferink J, Weighardt H, Scheu S
Authors: Peluso MJ, DeLuca MA, Dagna L, Garg B, Hafler JP, Kiguli-Malwadde E, Mayanja-Kizza H, Maley MA, Rohrbaugh RM
